Anthropic reports early Claude results across drug discovery and development
Anthropic has reported early work with six drug-development organisations and its own research programs. In one BigHat collaboration, Claude-assisted teams tested about 1,010 antibody variants over ten weeks and improved binding, stability and aggregation measures. Other projects cover clinical-trial planning, regulatory documents, target assessment, rare disease programs and laboratory-directed agent workflows.